找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: HCV: The Journey from Discovery to a Cure; Volume I Michael J. Sofia Book 2019 Springer Nature Switzerland AG 2019 HCV genome.Molecular Vir

[復(fù)制鏈接]
查看: 32767|回復(fù): 56
樓主
發(fā)表于 2025-3-21 16:49:19 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱HCV: The Journey from Discovery to a Cure
副標(biāo)題Volume I
編輯Michael J. Sofia
視頻videohttp://file.papertrans.cn/421/420175/420175.mp4
概述Provides a comprehensive compilation of discoveries that led to the cure for HCV by the leading researchers in the field.Traces all aspects of HCV research that contributed to the development of key d
叢書名稱Topics in Medicinal Chemistry
圖書封面Titlebook: HCV: The Journey from Discovery to a Cure; Volume I Michael J. Sofia Book 2019 Springer Nature Switzerland AG 2019 HCV genome.Molecular Vir
描述Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide..This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is t
出版日期Book 2019
關(guān)鍵詞HCV genome; Molecular Virology; HCV replicon system; IFN therapy; Polymerase Inhibitors; Sofosbuvir; Becla
版次1
doihttps://doi.org/10.1007/978-3-030-28207-3
isbn_softcover978-3-030-28209-7
isbn_ebook978-3-030-28207-3Series ISSN 1862-2461 Series E-ISSN 1862-247X
issn_series 1862-2461
copyrightSpringer Nature Switzerland AG 2019
The information of publication is updating

書目名稱HCV: The Journey from Discovery to a Cure影響因子(影響力)




書目名稱HCV: The Journey from Discovery to a Cure影響因子(影響力)學(xué)科排名




書目名稱HCV: The Journey from Discovery to a Cure網(wǎng)絡(luò)公開度




書目名稱HCV: The Journey from Discovery to a Cure網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱HCV: The Journey from Discovery to a Cure被引頻次




書目名稱HCV: The Journey from Discovery to a Cure被引頻次學(xué)科排名




書目名稱HCV: The Journey from Discovery to a Cure年度引用




書目名稱HCV: The Journey from Discovery to a Cure年度引用學(xué)科排名




書目名稱HCV: The Journey from Discovery to a Cure讀者反饋




書目名稱HCV: The Journey from Discovery to a Cure讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-22 00:19:25 | 只看該作者
板凳
發(fā)表于 2025-3-22 01:00:21 | 只看該作者
地板
發(fā)表于 2025-3-22 04:50:50 | 只看該作者
https://doi.org/10.1057/9781137339096hepatocellular carcinoma. The HCV genome was cloned molecularly in 1989, and around 25?years later, antiviral therapy has been established that eliminates the virus in more than 95% of infected individuals. To reach this goal, several hurdles had to be overcome, a major one having been the developme
5#
發(fā)表于 2025-3-22 11:04:48 | 只看該作者
6#
發(fā)表于 2025-3-22 15:27:02 | 只看該作者
7#
發(fā)表于 2025-3-22 18:53:12 | 只看該作者
The Chinese Path Toward a Leaner Governmenteffort on the discovery and development of interferon (IFN)-free therapies that are well tolerated and have increased cure rates. This chapter describes the discovery and development of sofosbuvir, the first live-targeting prodrug of a nucleotide analog, and contains a detailed overview of the synth
8#
發(fā)表于 2025-3-23 00:01:24 | 只看該作者
A Modified Vision of Divine Determination, The history of the discovery and optimization of leads acting at each of these sites is discussed. The many clinical candidates that emerged from these efforts are described, together with their impact on emerging regimens of increasing effectiveness.
9#
發(fā)表于 2025-3-23 05:26:21 | 只看該作者
HJD-04: The Chinese-Developed Systemass of indolobenzazepines. Within this research, a strategic decision to abandon a highly potent but physiochemically problematic series in favor of one of lower molecular weight and potency was key in the realization of the program’s objectives. Subsequent cycles of analog design incorporating prog
10#
發(fā)表于 2025-3-23 07:13:18 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 07:08
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
清镇市| 比如县| 赣榆县| 达尔| 沂源县| 绥阳县| 六枝特区| 府谷县| 乌兰浩特市| 荣昌县| 汝城县| 南宁市| 阜宁县| 长岭县| 嘉荫县| 宁河县| 大方县| 宿松县| 西丰县| 古交市| 潮州市| 南通市| 玛纳斯县| 遵义市| 云龙县| 苏尼特左旗| 鹤岗市| 普安县| 区。| 嘉定区| 大埔县| 额敏县| 嘉兴市| 常山县| 蕲春县| 东平县| 聊城市| 松溪县| 乾安县| 灵台县| 西青区|